Clinical Contribution of Next-Generation Sequencing Multigene Panel Testing for BRCA Negative High-Risk Patients With Breast Cancer


ECE SOLMAZ A. , YENİAY L. , GÖKMEN E. , ZEKİOĞLU O. , HAYDAROĞLU A. , GÜNHAN BİLGEN I. , ...More

CLINICAL BREAST CANCER, vol.21, no.6, 2021 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 21 Issue: 6
  • Publication Date: 2021
  • Doi Number: 10.1016/j.clbc.2021.04.002
  • Title of Journal : CLINICAL BREAST CANCER
  • Keywords: Hereditary cancer susceptibility genes, NGS, Breast cancer, Next-generation sequencing, Multi-gene panel, BRCA1/2, GERMLINE MUTATIONS, HEREDITARY BREAST, OVARIAN-CANCER, GENE, SUSCEPTIBILITY, PALB2, MULTIPLE, PROTEIN, BRIP1

Abstract

Next-generation sequencing has increased the detection of pathogenic/likely pathogenic variants in genes other than BRCA1/2. This study included 188 high-risk patients with BRCA1/2-negative breast cancer tested with a multigene cancer panel. Among 188 proband cases, 18 variants in 21 patients (11.1%) were classified as pathogenic/likely pathogenic. A multigene panel increased the diagnosis success in patients with BRCA1/2-negative high-risk breast cancer.